MILTENYI BIOTEC BV & CO KG

Their core work

Miltenyi Biotec is a major German biotechnology company specializing in cell separation, cell therapy manufacturing, and flow cytometry instruments. In H2020 projects, they contribute their proprietary cell isolation and processing technologies — essential infrastructure for producing advanced therapy medicinal products (ATMPs) including CAR-T cells, NK cells, and other engineered immune cells. They serve as a critical technology provider enabling the transition of cell and gene therapies from lab-scale research to GMP-compliant clinical manufacturing. Their instruments and reagents are embedded across the European cell therapy research ecosystem.

What they specialise in

How they've shifted over time

In 2016–2019, Miltenyi's H2020 portfolio was tightly focused on cancer immunotherapy and cell therapy manufacturing — CAR-T engineering, NK cell production, GMP compliance, and cell isolation automation. From 2020 onward, their involvement broadened significantly into neuroscience (cell reprogramming for Parkinson's and Huntington's), advanced imaging modalities (photoacoustic, infrared microscopy, cytometry), and developmental biology (gonadal cell atlases). This evolution suggests a company expanding beyond its immune-oncology core into regenerative medicine and next-generation analytical instruments.

Miltenyi is diversifying from immune cell processing into neuroregeneration and advanced optical/cytometry platforms, positioning for the next wave of cell-based therapies beyond oncology.

How they like to work

Miltenyi operates almost exclusively as a participant or specialist partner — they coordinated only 1 of 15 projects (CARAT), preferring to contribute technology and manufacturing expertise to consortia led by academic institutions. With 161 unique partners across 20 countries, they are a highly networked hub rather than a loyal repeat-partner organization. Their consistent presence in MSCA training networks (6 projects) signals a willingness to invest in workforce development alongside technology transfer.

Miltenyi has collaborated with 161 unique partners across 20 countries, making them one of the most broadly connected biotech companies in the H2020 cell therapy space. Their network spans all major European research nations with particularly strong ties to academic medical centers and training networks.

What sets them apart

Miltenyi occupies a rare position as an industrial-scale cell processing technology provider embedded in academic research consortia — most partners of similar size either lead projects or stay at arm's length. Their instruments and reagents are often the de facto standard for cell isolation in European labs, making them a near-essential partner for any consortium working on cell-based ATMPs. For consortium builders, Miltenyi brings not just equipment but deep regulatory knowledge of GMP manufacturing for advanced therapies.

Highlights from their portfolio

• CARAT
  Miltenyi's only coordinated project — focused on their core CAR-T manufacturing expertise, signaling strategic priority in this area.
• FAIR CHARM
  Largest single EC contribution (EUR 792,408) and represents their expansion into infrared microscopy and advanced cytometry instruments.
• T2EVOLVE
  Major pan-European effort to accelerate CAR/TCR-T cell therapy access — positions Miltenyi at the center of Europe's engineered cell therapy ecosystem.